FDA grants SeaStar Medical breakthrough device designation for ICU SCD therapy
FDA granted SeaStar Medical a Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult patients with sepsis or a septic condition.
FDA granted SeaStar Medical a Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult patients with sepsis or a septic condition.